Efficacy and Safety of SYR-322 Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus. - Full Text View

Sponsor:	Takeda Global Research & Development Center, Inc.
Information provided by:	Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier:	NCT00328627

Purpose

The purpose of this study is to evaluate the safety and efficacy of SYR-322 taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

Condition	Intervention	Phase
Type 2 Diabetes Mellitus	Drug: SYR-322 Drug: SYR-322 and pioglitazone Drug: Placebo Drug: Pioglitazone	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Pioglitazone Pioglitazone hydrochloride Alogliptin

U.S. FDA Resources

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:

Change from Baseline in Glycosylated Hemoglobin [ Time Frame: Week 26 or Final Visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change from Baseline in Glycosylated Hemoglobin [ Time Frame: Weeks 4, 8, 12, 16, 20 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Fasting Plasma Glucose [ Time Frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Marked Hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL). [ Time Frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Rescue. [ Time Frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Fasting Proinsulin [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Insulin. [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Proinsulin/Insulin ratio [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in C-peptide [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin less than or equal to 6.5%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin less than or equal to 7.0%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin less than or equal to 7.5%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 0.5%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.0%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.5%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 2.0%. [ Time Frame: Week 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Total Cholesterol. [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Low-Density Lipoprotein. [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in High-Density Lipoprotein. [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Triglycerides. [ Time Frame: Weeks 4, 8, 12, 16, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Nuclear Magnetic Resonance Lipid Fractionation [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from baseline in Free Fatty Acids [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Plasminogen Activator Inhibitor-1. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in high-sensitivity C-Reactive Protein. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Adiponectin. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Body Weight. [ Time Frame: Weeks 8, 12, 20, and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Calculated Homeostatic Model Assessment Insulin Resistance. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Homeostatic Model Assessment Beta Cell Function. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Apolipoprotein A1. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Apolipoprotein A2. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Apolipoprotein B. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Apolipoprotein C-III. [ Time Frame: Weeks 12 and 26 or Final Visit. ] [ Designated as safety issue: No ]

Enrollment:	1554
Study Start Date:	May 2006
Study Completion Date:	March 2008
Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: SYR-322 SYR-322 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
2: Experimental	Drug: SYR-322 and pioglitazone SYR-322 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3: Experimental	Drug: SYR-322 and pioglitazone SYR-322 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
4: Experimental	Drug: SYR-322 and pioglitazone SYR-322 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
5: Experimental	Drug: SYR-322 SYR-322 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
6: Experimental	Drug: SYR-322 and pioglitazone SYR-322 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
7: Experimental	Drug: SYR-322 and pioglitazone SYR-322 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
8: Experimental	Drug: SYR-322 and pioglitazone SYR-322 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
9: Placebo Comparator	Drug: Placebo SYR-322 placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
10: Active Comparator	Drug: Pioglitazone SYR-322 placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
11: Active Comparator	Drug: Pioglitazone SYR-322 placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
12: Active Comparator	Drug: Pioglitazone SYR-322 placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.

Detailed Description:

Over the past 30 years, the prevalence of diabetes has increased dramatically throughout the world due to population growth, aging, urbanization, increasing obesity, and physical inactivity. The total number of people with type 2 diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. The incidence of type 2 diabetes mellitus in the United States alone is expected to increase from approximately 17 to 30.3 million by the year 2030. Type 2 diabetes mellitus is associated with a number of long-term microvascular and macrovascular complications associated with a reduced quality of life and increased morbidity and mortality. It is anticipated that the increasing incidence of type 2 diabetes mellitus will place an ever-increasing burden on families, increase national expenditures for health care services, and decrease worker productivity.

Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of antidiabetic medications with different mechanisms of action including insulin and insulin analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha-glucosidase, analogs of glucagon-like peptide-1 and synthetic analogues of human amylin. Despite the variety of medications, many have clinically important or potentially life-threatening side effects, restricted use in many subpopulations, concerns with long-term tolerability, and challenges related to compliance due to side effects and route of administration. All of these reasons contribute to the difficulties patients have achieving the target glycosylated hemoglobin level less than 7%.

SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4 enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus.

Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone is a potent and highly selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output.

Given the complementary mechanisms of action of alogliptin (stimulation of insulin secretion) and pioglitazone (enhancement of insulin sensitivity), the goal of this study is to evaluate the efficacy of the combination of alogliptin with pioglitazone in subjects who are inadequately controlled on metformin. Study participation is anticipated to be approximately 7 months.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men or women with a historical diagnosis of type 2 diabetes mellitus who were treated with metformin greater than or equal to 1500 mg alone but were experiencing inadequate glycemic control.
A stable dose of metformin of greater than or equal to 1500 mg or maximum tolerated dose.
No treatment with antidiabetic agents other than metformin within the 2 months prior to Screening.
A body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2.
Fasting C-peptide greater than or equal to 0.8 ng/mL.
Regular use of other, non-excluded medications was allowed if a stable dose had been established for at least 4 weeks prior to Screening.
Systolic blood pressure less than or equal to 160 mm Hg and diastolic pressure less than or equal to 100 mm Hg.
Hemoglobin greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
Alanine aminotransferase less than or equal to 2.5 times the upper limit of normal.
Serum creatinine less than 1.5 mg/dL for men and less than 1.4 mg/dL for women.
Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject was clinically euthyroid.
Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
No major illness or debility that in the investigator's opinion prohibited the subject from completing the study.

Exclusion Criteria:

Urine albumin/creatinine ratio greater than 113 mg/mmol at Screening.
A history of cancer, other than squamous cell or basal cell carcinoma of the skin, that had not been in full remission for at least 5 years prior to Screening.
A history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
A history of treated diabetic gastroparesis.
New York Heart Association Class III or IV heart failure regardless of therapy.
History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
History of any hemoglobinopathy.
History of infection with hepatitis B, hepatitis C or human immunodeficiency virus.
History of a psychiatric disorder that could have affected the subject's ability to participate in the study.
History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
A history of alcohol or substance abuse within 2 years prior to Screening.
Receipt of any investigational drug within 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within 3 months prior to Screening.
Previous participation in an investigational study of alogliptin.
Hypersensitive to pioglitazone, alogliptin, or other excipients.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00328627

Show 90 Study Locations

Sponsors and Collaborators

Takeda Global Research & Development Center, Inc.

Investigators

Study Director:

VP Biological Sciences

Takeda Global Research & Development Center, Inc.

More Information

Additional Information:

ACTOS® Package Insert This link exits the ClinicalTrials.gov site

FDA Safety Alerts and Recalls This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science )
Study ID Numbers:	01-05-TL-322OPI-001, 2006-000694-30, SYR110322
Study First Received:	May 19, 2006
Last Updated:	July 30, 2009
ClinicalTrials.gov Identifier:	NCT00328627 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Takeda Global Research & Development Center, Inc.:

Diabetes Mellitus, Type 2
Drug Therapy
Diabetes Mellitus, Non Insulin Dependent
Glucose Intolerance
Hyperglycemia

Additional relevant MeSH terms:

Hypoglycemic Agents
Metabolic Diseases
Pioglitazone
Physiological Effects of Drugs
Diabetes Mellitus, Type 2

Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010